| Literature DB >> 21466613 |
Tomoya Hirosawa1, Hiroki Torikai, Mayumi Yanagisawa, Michi Kamei, Nobuhiko Imahashi, Ayako Demachi-Okamura, Miyoko Tanimoto, Keiko Shiraishi, Mamoru Ito, Koichi Miyamura, Kiyosumi Shibata, Fumitaka Kikkawa, Yasuo Morishima, Toshitada Takahashi, Nobuhiko Emi, Kiyotaka Kuzushima, Yoshiki Akatsuka.
Abstract
Partial human leukocyte antigen (HLA)-mismatched hematopoietic stem cell transplantation (HSCT) is often performed when an HLA-matched donor is not available. In these cases, CD8(+) or CD4(+) T cell responses are induced depending on the mismatched HLA class I or II allele(s). Herein, we report on an HLA-DRB1*08:03-restricted CD8(+) CTL clone, named CTL-1H8, isolated from a patient following an HLA-DR-mismatched HSCT from his brother. Lysis of a patient Epstein-Barr virus-transformed B cell line (B-LCL) by CTL-1H8 was inhibited after the addition of blocking antibodies against HLA-DR and CD8, whereas antibodies against pan-HLA class I or CD4 had no effect. The 1H8-CTL clone did not lyse the recipient dermal fibroblasts whose HLA-DRB1*08:03 expression was upregulated after 1 week cytokine treatment. Engraftment of HLA-DRB1*08:03-positive primary leukemic stem cells in non-obese diabetic/severe combined immunodeficient/γc-null (NOG) mice was completely inhibited by the in vitro preincubation of cells with CTL-1H8, suggesting that HLA-DRB1*08:03 is expressed on leukemic stem cells. Finally, analysis of the precursor frequency of CD8(+) CTL specific for recipient antigens in post-HSCT peripheral blood T cells revealed a significant fraction of the total donor CTL responses towards the individual mismatched HLA-DR antigen in two patients. These findings underscore unexpectedly significant CD8 T cell responses in the context of HLA class II.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21466613 DOI: 10.1111/j.1349-7006.2011.01949.x
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716